Skip to main content

MSD and VNVC plan vaccine technology transfer in Vietnam

VNVC is investing more than ₫2.5 trillion in the first phase of a Tay Ninh vaccine plant, with commercial production scheduled for 2029.

By Nadia Hassan

Vaccine vials and laboratory equipment in a manufacturing facility
Photo: VnExpress International

MSD and Vietnam Vaccine Joint Stock Company (VNVC) said on Nov. 18 that they intend to work together on transferring vaccine technology and manufacturing vaccines in Vietnam. The proposed collaboration aims to build the country's capacity to produce vaccines domestically.

Under the plan, MSD would share scientific and technical expertise with VNVC, alongside manufacturing capabilities and quality-management processes. The announcement came during a Vietnam visit by MSD executives and was attended by government officials, including Health Minister Dao Hong Lan.

VNVC chairman and CEO Ngo Chi Dung said the companies were exploring a broader partnership after several years of working together to supply millions of vaccine doses annually in Vietnam. He said VNVC had invested in a manufacturing facility and was preparing to acquire and progressively master advanced technologies.

VNVC's plant in Tay Ninh Province has an initial-phase investment exceeding ₫2.5 trillion and is designed for annual output of 100-120 million doses. Construction is expected to conclude in 2027, followed by the start of operations in 2028. Commercial production is scheduled for 2029.

The company aims for the facility to meet manufacturing requirements set by the World Health Organization, European Union and U.S. Food and Drug Administration. VNVC says the project forms part of its longer-term effort to develop domestic vaccine production and lessen dependence on imports.

Keep reading: Business & Companies

All Business & Companies stories

Latest in Finance

All latest